SL 251188
Latest Information Update: 17 Mar 2009
Price :
$50 *
At a glance
- Originator Sanofi-Synthelabo
- Class Smoking cessation therapies
- Mechanism of Action Monoamine oxidase B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease; Smoking withdrawal
Most Recent Events
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 25 Sep 2002 Discontinued - Phase-I for Alzheimer's disease in Europe (unspecified route)
- 06 Dec 1999 New profile